{"filings":[{"id":452759,"accession_number":"0001493152-26-023352","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2026-05-15T12:05:34+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PAVmed Q1 GAAP net loss $7.0M; Lucid Diagnostics revenue $1.3M, 3,177 tests","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $7.0M ($4.42 diluted EPS); non-GAAP adjusted loss $1.9M ($1.17 per share).","Cash and equivalents $6.5M at Mar 31, up from $1.5M at Dec 31, 2025.","Lucid Diagnostics Q1 EsoGuard revenue $1.3M, 3,177 tests processed; raised $17M in public offering, proforma cash $45M.","Veris Health advancing implantable physiological monitor towards FDA 510(k) submission.","PAVmed relaunched medical device portfolio including PortIO and Duke-licensed endoscopic imaging."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":22000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106331,"accession_number":"0001493152-26-013477","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PAVmed completes $45M financing, eliminates convertible debt; Q4 net loss $1.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PAVmed completed $30M Series D preferred offering and $15M senior secured note, eliminating all outstanding convertible securities.","GAAP net loss attributable to common stockholders $1.8M ($2.05 per share diluted); non-GAAP adjusted loss $0.9M ($1.05 per share).","Lucid Diagnostics recognized $1.5M EsoGuard revenue in Q4 2025, processed 3,664 tests; awarded VA contract for ~9M veterans.","Veris Health completed EHR integration with OSU James Cancer Hospital; targeting late 2026 FDA submission for implantable monitor.","PAVmed appointed Joseph Virgilio as CBO of Medical Devices and licensed endoscopic esophageal imaging technology from Duke University."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106330,"accession_number":"0001493152-26-013264","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"PAVmed stockholders approve stock issuance, charter amendment, and equity plan increase at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved issuance of shares upon conversion of 60,000 Series D Preferred shares and shares under Convertible Note (640,946 for, 72,380 against).","Approved charter amendment enabling director removal with or without cause by majority vote (858,651 for, 60,825 against); filed and effective March 27, 2026.","Approved amendment to 2014 Long-Term Incentive Equity Plan, increasing authorized shares by 1,500,000 to 1,713,517 (756,683 for, 162,305 against).","Stockholders representing 54.1% of voting power were present at the special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106329,"accession_number":"0001493152-26-005023","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","3.03","5.03","7.01","9.01"],"status":"ready","headline":"PAVmed closes $30M Series D Preferred and $15M Note, retires all convertible securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $30M from Series D Preferred; warrants exercisable for additional $30M upon positive Medicare LCD for EsoGuard.","New $15M senior secured note with 15% interest, matures Feb 2029, to existing investor.","Used $22.3M cash + $15M note to redeem all Series C Preferred and retire convertible debt; net cash $7.7M.","Series D convertible at $6.50/share; special meeting by April 30, 2026 to seek stockholder approval for conversion.","Eliminates legacy convertible overhang; PAVmed holds 31M shares of Lucid Diagnostics (Nasdaq: LUCD)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106328,"accession_number":"0001493152-26-003409","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PAVmed regains Nasdaq $1 minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Jan 21, 2026 that it regained compliance with Listing Rule 5550(a)(2).","Compliance based on closing bid price at $1 or greater from Jan 2 through Jan 19, 2026.","Prior non-compliance notice was issued on Jan 23, 2025; now cured."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122653,"accession_number":"0001493152-25-029510","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["3.03","5.03","7.01","2.02","9.01"],"status":"ready","headline":"PAVmed announces 1-for-30 reverse stock split effective Jan 2, 2026 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-30 reverse split effective Jan 2, 2026; authorized shares reduced from 250M to 25M.","Split intended to regain compliance with Nasdaq $1.00 minimum bid price requirement.","No fractional shares; all fractional shares rounded up to nearest whole share.","CUSIP changes to 70387R 502; ticker PAVM unchanged.","Stockholder approved at Dec 5 special meeting; board set ratio on Dec 8, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122652,"accession_number":"0001493152-25-026368","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"PAVmed shareholders approve reverse stock split (1:10–1:30) and authorized share reduction to 25M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split (ratio 1:10–1:30, board to decide) and authorized share reduction from 250M to 25M.","Vote: 19,310,685 For, 974,164 Against, 13,241 Abstain; 65.8% of voting power present at Dec 5 special meeting.","Board expects to file certificate of amendment with Delaware Secretary of State as soon as practicable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122651,"accession_number":"0001493152-25-022122","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PAVmed Q3 net loss $6.3M; Veris relaunches implant monitor; Lucid gets Medicare support","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $6.3M ($0.29 diluted EPS); non-GAAP adj loss $0.4M ($0.02) for Q3 2025.","Lucid Diagnostics: $1.2M EsoGuard revenue, 2,841 tests processed; CAC unanimously supported Medicare coverage.","Veris Health launched commercial phase of OSU partnership, relaunched implantable monitor for planned 2026 FDA submission.","PAVmed signed LOI with Duke University to license endoscopic esophageal imaging technology via new subsidiary.","PAVmed cash $3.1M (Sep 30) vs $1.2M (Dec 31, 2024); Lucid netted ~$27M from public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":19000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139352,"accession_number":"0001493152-25-013048","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PAVmed subsidiary Lucid Diagnostics closes $28.75M stock offering at $1.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lucid Diagnostics sold 28.75M shares at $1.00 each via underwritten offering.","Underwriters' option for 3.75M shares exercised in full at closing.","Net proceeds expected to be approximately $26.9 million after expenses.","Funds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139351,"accession_number":"0001641172-25-023729","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PAVmed Q2 net loss $13.3M ($0.74/share); Lucid EsoGuard rev $1.2M on 2,756 tests","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $13.3M ($0.74 diluted EPS); non-GAAP adjusted loss $1.8M ($0.11/share).","Lucid processed 2,756 EsoGuard tests and recognized $1.2M revenue; CAC meeting on Medicare LCD set Sept 4.","Lucid raised $16.1M in public offering; Veris completed $2.5M direct equity financing at $35M pre-money valuation.","Veris advancing implantable monitor through FDA clearance; partnered with OSU-The James for Cancer Care Platform.","Cash $4.0M at June 30 vs $1.2M at Dec 31, 2024; operating expenses $4.7M including $0.2M stock comp."],"consensus_eps_estimate":null,"consensus_eps_actual":0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":14000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139350,"accession_number":"0001493152-25-011491","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PAVmed receives Nasdaq extension to Jan 2026 to meet $1 minimum bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company failed to regain compliance by initial July 22, 2025 deadline after Jan 23 notice.","Nasdaq granted additional 180-day extension until January 19, 2026 for 10 consecutive $1 closing bids.","Stock continues trading under PAVM; PAVmed says it will consider all available options.","Failure to cure during extension could lead to delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156931,"accession_number":"0001641172-25-016227","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"PAVmed subsidiary Veris Health raises $2.5M in equity and warrant offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Veris sold 1,785,714 common shares and warrants at $1.40 per share unit.","Gross proceeds of ~$2.5M for development of implantable physiological monitor and working capital.","After offering, PAVmed owns 75.3% of Veris on a fully-diluted basis.","Warrants exercisable after 6 months at $1.40, expire 5 years from exercise or 60 days post-FDA approval.","Investors granted anti-dilution protection and 100% participation rights in future equity raises."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156930,"accession_number":"0001641172-25-015612","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"PAVmed shareholders re-elect directors, approve equity plan increase and stock issuance at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected Lishan Aklog (7.15M for, 2.08M withheld) and Michael Glennon (7.22M for, 2.01M withheld) as Class C directors.","Approved issuance of common stock upon exercise of pre-funded warrants from Feb 2025 private placement (4.65M for, 0.29M against).","Approved amendment to 2014 equity plan increasing authorized shares by 2.5M, from 2,412,140 to 4,912,140 shares.","Advisory say-on-pay passed with 7.11M for, 0.38M against; ratification of Marcum LLP as auditor for 2025 passed with 14.22M for.","Turnout was ~77.2% of outstanding shares entitled to vote (common + preferred as-converted)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156929,"accession_number":"0001641172-25-010536","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PAVmed Q1 GAAP net income $17.7M, adjusted loss $0.9M; Lucid raises $30.6M, cash >$40M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income attributable to common stockholders $17.7M ($0.34 diluted EPS); non-GAAP adjusted loss $0.9M ($0.07 per share).","Lucid Diagnostics (LUCD) recognized $0.8M EsoGuard revenue, processed 3,034 tests; raised $30.6M net from stock offerings, ended Q1 with over $40M pro forma cash.","Veris Health completed financing, resumed development of implantable monitor; completed pilot with Ohio State's James Cancer Hospital, planning commercial partnership.","PAVmed cash and cash equivalents $2.7M at March 31, 2025, up from $1.2M at Dec 31, 2024; operating expenses $5.5M including $1.0M stock-based comp.","PAVmed seeking to expand into biopharma, evaluating clinical and late preclinical-stage assets for new subsidiary."],"consensus_eps_estimate":null,"consensus_eps_actual":0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":8000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156928,"accession_number":"0001641172-25-006250","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"PAVmed appoints CBIZ CPAs as new auditor after Marcum acquisition; no disagreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned as auditor on April 23, 2025 following its attest business acquisition by CBIZ CPAs.","Audit committee approved engagement of CBIZ CPAs as successor independent registered public accounting firm on same date.","Marcum's audit reports for 2024 and 2023 contained an explanatory paragraph regarding going concern.","No disagreements or reportable events occurred with Marcum during fiscal 2024, 2023, or through resignation date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156927,"accession_number":"0001641172-25-005279","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"PAVmed enters $2.88M at-the-market equity offering agreement with Maxim Group","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM offering up to $2,880,000 of common stock under shelf registration effective April 15, 2025.","Maxim Group LLC receives 3.0% commission; Company reimburses legal fees up to $50k initial plus $5k/quarter.","Proceeds to be used for working capital and general corporate purposes.","Agreement terminable by either party on 10 business days' notice; Agent may terminate immediately in certain circumstances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156926,"accession_number":"0001641172-25-003741","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PAVmed subsidiary Lucid Diagnostics closes 14.4M share offering raising ~$16.1M net","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lucid Diagnostics closed sale of 14,375,000 shares at $1.20 each, including full exercise of underwriters' option.","Net proceeds expected to be approximately $16.1 million after underwriting discounts and expenses.","Proceeds will be used for working capital and general corporate purposes.","Offering was made under Lucid's existing shelf registration statement (Form S-3) and prospectus supplement dated April 9, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175311,"accession_number":"0001641172-25-000517","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PAVmed reports Q4 net income $1.3M; Lucid record tests, Veris financing, debt restructured","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $1.3M ($0.12 diluted EPS); non-GAAP adjusted loss $0.7M ($0.06) per share.","Lucid processed 4,042 EsoGuard tests in Q4 (+84% YoY); secured first insurance coverage from Highmark Blue Cross Blue Shield.","Veris closed ~$2.4M private placement at $35M pre-money valuation to advance implantable monitor toward FDA clearance.","PAVmed cash $1.2M at Dec 31; pro forma $3.6M including Q1 2025 private placement.","Deconsolidation of Lucid and convertible debt restructuring added ~$25M to equity, regaining Nasdaq minimum equity compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175310,"accession_number":"0001493152-25-009698","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PAVmed subsidiary Lucid Diagnostics closes ~$15.3M equity offering at $1.10/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lucid Diagnostics sold 13.9M shares at $1.10 each, gross proceeds ~$15.3M.","Net proceeds estimated ~$14.5M after placement agent fees and expenses.","Proceeds expected to be used for working capital and general corporate purposes.","Offering closed on March 5, 2025, pursuant to an existing shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175309,"accession_number":"0001493152-25-007902","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"PAVmed raises $2.37M via PIPE of common stock and pre-funded warrants with Veris subsidiary shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sale of 2,574,350 shares and 756,734 pre-funded warrants at $0.7115/unit; Veris issues 677,143 shares to investors.","Gross proceeds of $2.37M; proceeds to fund Veris' implantable physiological monitor and working capital.","Company grants anti-dilution protection via additional Veris shares; restricts indebtedness until Aug 18, 2026.","Registration rights granted; stockholder vote required for warrant shares by June 30, 2025.","Transaction exempt under Section 4(a)(2) and Regulation D; no public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175308,"accession_number":"0001493152-25-007094","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PAVmed regains Nasdaq compliance after equity actions; enters 1-year monitoring","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notified Feb 14, 2025 that it regained compliance with Nasdaq Listing Rule 5550(b)(1) ($2.5M equity).","Regained compliance via exchange of $22.3M notes for Series C preferred, $2.653M new preferred issuance, and Lucid Diagnostics deconsolidation.","Subject to one-year Mandatory Panel Monitor until Feb 14, 2026; new deficiency could trigger delisting.","Company previously received hearing panel extension to Jan 31, 2025 after failing market value rule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175307,"accession_number":"0001493152-25-003631","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["3.01","3.02","3.03","9.01"],"status":"ready","headline":"PAVmed receives Nasdaq minimum bid price deficiency notice; sells Series C preferred shares","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice on Jan 23: common stock closing bid below $1 for 30 consecutive days; 180-day cure period until July 22, 2025.","To regain compliance, closing bid must be at least $1 for 10 consecutive business days.","On Jan 24, sold 2,653 Series C Convertible Preferred shares for ~$2.653M via cancellation of unsecured debt.","Conversion at voluntary price $1.068/share would issue ~2.48M common shares; at floor $0.2136, ~12.42M shares.","Company intends to consider all available options to regain compliance with Nasdaq listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175306,"accession_number":"0001493152-25-003053","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["3.01","3.02","3.03","5.03","8.01","9.01"],"status":"ready","headline":"PAVmed exchanges $22.35M of convertible notes for Series C preferred; targets Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged $22,347,543 in principal plus interest of Senior Secured Convertible Notes for 22,347 Series C Preferred shares.","Remaining outstanding principal on Convertible Notes is approximately $6.6 million.","Potential dilution: at voluntary conversion price $1.068/share, ~20.9M common shares; at floor $0.2136, ~104.6M shares.","Company executed exchange to bolster stockholders' equity to meet Nasdaq minimum of $2.5M; compliance deadline Jan 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175305,"accession_number":"0001493152-25-002398","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"PAVmed stockholders approve 4x increase in authorized shares to 250M and Series C Preferred issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amending the certificate of incorporation to increase authorized common shares from 50M to 250M, effective Jan 15, 2025.","Stockholders also approved the issuance of common stock upon conversion of Series C Convertible Preferred shares.","Series C Preferred will be issued under a Debt Exchange Agreement and a Securities Purchase Agreement, both dated November 2024.","Company expects to consummate the Series C Preferred issuance and debt exchange by January 31, 2025.","Vote tallies: For amendment 5.23M vs 0.72M against; for issuance 5.48M vs 0.46M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192264,"accession_number":"0001493152-24-048173","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2024-11-29T23:59:59+00:00","items":["1.01","2.03","3.03","9.01"],"status":"ready","headline":"PAVmed sub Lucid closes $21.95M convertible note placement; net $18.3M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Lucid Diagnostics (PAVmed sub) closed $21.95M in Senior Secured Convertible Notes to accredited investors.","Gross proceeds $21.95M; net proceeds after repaying prior 2023 Convertible Note ~$18.3M.","Transaction includes Registration Rights, Guaranty, and Security Pledge Agreements.","Notes are senior secured and convertible; terms incorporated by reference from Nov 29 filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192263,"accession_number":"0001493152-24-047156","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["1.01","3.02","3.03","9.01"],"status":"ready","headline":"PAVmed exchanges $22.3M convertible notes for Series C Preferred Stock and enters separate $2.65M purchase","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged $22,347,543 principal amount of Senior Secured Convertible Notes for 22,347 shares of Series C Preferred Stock.","Series C Preferred Stock carries 7.875% annual dividend, convertible at $1.068 per share, and redeemable at 132.5% of stated value.","Company will seek stockholder approval by Jan 31, 2025 to increase authorized common stock from 50M to 250M shares.","Separate Securities Purchase Agreement for $2,652,456.76 of unsecured debt cancelled in exchange for 2,653 additional Series C Preferred shares.","Outstanding convertible note balance reduced to approximately $6.4 million after exchange; remaining note maturity extended to Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192262,"accession_number":"0001493152-24-045362","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PAVmed reports Q3 GAAP net income $64.3M driven by deconsolidation; Lucid EsoGuard revenue record $1.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Lucid Q3 EsoGuard revenue $1.2M, a record; 2,787 commercial tests; October single-month record >1,400 tests.","GAAP net income $64.3M ($1.44 diluted EPS) largely due to Lucid deconsolidation; non-GAAP adjusted loss $5.4M ($0.54/share).","Cash and equivalents $0.8M as of Sept 30, 2024, down from $19.6M at Dec 31, 2023.","PAVmed deconsolidated Lucid on Sept 10; reached agreement to exchange $25M convertible debt for preferred equity to regain Nasdaq compliance; extension to Jan 31, 2025.","Veris completed pilot with Ohio State's James Cancer Hospital and awarded $1.8M NIH grant."],"consensus_eps_estimate":null,"consensus_eps_actual":0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":3000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208745,"accession_number":"0001493152-24-036380","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["2.01","5.02","3.01","7.01","9.01"],"status":"ready","headline":"PAVmed deconsolidates Lucid Diagnostics, expects ~$70M gain; faces Nasdaq delisting, appoints new director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deconsolidated Lucid from financials; expects ~$70M non-cash gain in Q3 2024.","Pro forma stockholders' equity improves $9.7M but still deficit of ~$9.0M.","Received Nasdaq delisting notice for failing min market value; will appeal with hearing in Oct.","Dr. Cox and Harvey resigned from board; Dr. Agrawal appointed as Class B director.","PAVmed retains 31.3M Lucid shares (no change); deconsolidation does not affect ownership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208744,"accession_number":"0001493152-24-031471","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PAVmed Q2 GAAP net loss $10.9M; Lucid EsoGuard test volume record 3,147 (up 31% QoQ)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $1.0M from EsoGuard test; GAAP net loss attributable to common $10.9M ($1.19/sh).","Adjusted non-GAAP loss $7.7M ($0.84/sh). Cash and equivalents $25.5M at June 30, 2024.","Lucid commercial EsoGuard tests: 3,147 in Q2 (single-quarter record), +31% sequential, +44% YoY.","Lucid held productive meeting with CMS MAC Palmetto GBA's MolDX program for EsoGuard coverage.","Veris launched pilot with Ohio State's James Cancer Hospital; actively pursuing independent financing."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":2000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226483,"accession_number":"0001493152-24-024540","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"PAVmed Inc. stockholders re-elect directors and ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approximately 58.5% of outstanding shares were represented at the June 20, 2024 annual meeting.","James L. Cox, M.D. was re-elected with 2,177,207 votes for and 128,338 withheld (3,209,395 broker non-votes).","Debra J. White was re-elected with 2,234,311 votes for and 71,234 withheld (3,209,395 broker non-votes).","Ratification of Marcum LLP as independent auditor passed with 5,378,887 for, 92,448 against, and 43,605 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226482,"accession_number":"0001493152-24-019117","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"PAVmed reports Q1 2024 net loss of $22.8M; EsoGuard revenue flat QoQ at $1.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $22.8M ($2.62 per share); non-GAAP adjusted loss $8.6M ($0.99 per share).","EsoGuard revenue $1.0M (flat vs Q4 2023, +124% YoY); operating expenses $15.0M.","Lucid completed $29.8M Series B Preferred Stock offering to strengthen balance sheet.","Secured July 17, 2024 MolDX pre-submission meeting for technical assessment under LCD.","Veris Health completed MOU with Ohio State's James Cancer Hospital for pilot program."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":1000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226481,"accession_number":"0001493152-24-018036","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["1.01","3.03","3.02","5.03","9.01"],"status":"ready","headline":"PAVmed subsidiary Lucid Diagnostics raises $11.6M in Series B-1 preferred stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lucid Diagnostics, PAVmed's majority-owned subsidiary, raised ~$11.6M via Series B-1 Convertible Preferred Stock.","Sold approx 11,634 shares at $1,000/share to accredited investors; closed May 6, 2024.","Lucid filed Certificate of Designation for Series B-1 Preferred and entered Registration Rights Agreement.","Details are incorporated by reference from Lucid Diagnostics' separate 8-K filed May 7, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226480,"accession_number":"0001493152-24-017324","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PAVmed subsidiary Veris Health signs MOU with Ohio State cancer center for pilot of Veris Cancer Care Platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Veris and OSUCCC-James signed MOU to pilot the Veris Cancer Care Platform for cancer patients.","Pilot will enroll cancer patients in remote monitoring using VerisBox connected devices and patient smartphone app.","Veris is developing an implantable physiological monitor to interface with the platform, independent of patient compliance.","OSUCCC-James is a top NCI-designated comprehensive cancer center ranked among the best in the U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226479,"accession_number":"0001493152-24-016056","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"PAVmed extends $2M fee payment deadline on convertible notes to June 15, 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Letter agreement extends due date for $2,000,000 fee from April 25, 2024 to June 15, 2024.","Fee relates to one-year maturity extension and waiver of financial covenants on April 2022 and September 2022 notes.","No other modifications to the Notes; remaining terms unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245490,"accession_number":"0001493152-24-009898","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["1.01","3.03","3.02","9.01"],"status":"ready","headline":"PAVmed subsidiary Lucid Diagnostics raises $12.5M via Series B Preferred Stock offering and exchange","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lucid Diagnostics sold 12,495 shares of Series B Convertible Preferred at $1,000/share, raising $12.495M.","Investors exchanged 13,625 Series A and 10,670 Series A-1 shares for 31,790 Series B shares.","Closing on March 13, 2024; Lucid filed certificate of designation for Series B and amendment for Series A-1.","Registration rights agreement filed for resale of common stock issuable upon conversion of Series B Preferred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245489,"accession_number":"0001493152-24-009894","cik":1624326,"company_name":"PAVmed Inc.","ticker":"PAVM","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"PAVmed extends senior secured note maturities to 2025; pays $2M for covenant waiver","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["April 2022 Note maturity extended to April 4, 2025; September 2022 Note to September 8, 2025.","Holder waived financial covenant (30% market cap to principal ratio) from Dec 1 2023 to Aug 31 2024.","PAVmed to pay $2M cash (or agreed form) by April 25, 2024 for the amendment and waiver.","Covenant waiver conditioned on company market capitalization not falling below $75M during period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":44743965.27777778,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}